You have 9 free searches left this month | to do more
Showing 1 - 25 of
>10,000 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
U
Denosumab for Smoldering Multiple Myeloma
Recruiting
  • Smoldering Multiple Myeloma
  • Rochester, New York
    University of Rochester
2021-07-07
Jul 7, 2021
T
Multiple Myeloma Turkish Prospective Patient Registry
Recruiting
  • Multiple Myeloma
  • Relapse Multiple Myeloma
    • Istanbul, Turkey
      Medipol University
    2021-10-04
    Oct 4, 2021
    C
    Descartes-25 in Relapsed/Refractory Multiple Myeloma
    Not yet recruiting
    • Multiple Myeloma
    • Relapse Multiple Myeloma
    • (no location specified)
    2021-10-28
    Oct 28, 2021
    A
    Survival Outcomes of Multiple Myeloma Patients Admitted on Assiut Clinical Hematology Unit
    Not yet recruiting
    • Multiple Myeloma Outcone
    • Bone marrow biopsy and compete blood count
    • (no location specified)
    2021-11-02
    Nov 2, 2021
    Y
    Multiparametric Imaging in Multiple Myeloma - 2021
    Completed
    • Multiple Myeloma
    • C11 Methionine positron emission tomography
    • Boston, Massachusetts
      Massachusetts General Hospital
    2021-09-15
    Sep 15, 2021
    M
    TriPRIL CAR T Cells in Multiple Myeloma
    Recruiting
    • Multiple Myeloma
    • +2 more
    • TriPRIL CAR T Cells
    • +2 more
    • Boston, Massachusetts
      Massachusetts General Hospital Cancer Center
    2021-10-28
    Oct 28, 2021
    W
    A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab
    Recruiting
    • Multiple Myeloma
    • +2 more
    • New York, New York
      Weill Cornell Medicine - Multiple Myeloma Center
    2021-11-18
    Nov 18, 2021
    W
    Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients
    Not yet recruiting
    • Myeloma Multiple
    • +2 more
    • Aurora, Colorado
    • +2 more
    2021-08-26
    Aug 26, 2021
    H
    A Study of HG146 Capsule in Chinese Subjects With Relapsed and Refractory Multiple Myeloma
    Recruiting
    • Multiple Myeloma
    • Relapsed and Refractory Multiple Myeloma
    • Chengdu, Sichuan, China
      HitGen Inc
    2021-08-27
    Aug 27, 2021
    C
    a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma
    Recruiting
    • Multiple Myeloma
    • +2 more
    • BCMA targeted prime CAR-T cells
    • Kunming, Yunnan, China
      920th Hospital of Joint Logistics Support Force
    2021-07-30
    Jul 30, 2021
    C
    Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma
    Active, not recruiting
    • Smoldering Plasma Cell Myeloma
    • Duarte, California
      City of Hope Medical Center
    2021-08-11
    Aug 11, 2021
    C
    BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
    Recruiting
    • Multiple Myeloma
    • +2 more
    • BCMA CAR-T cells
    • Kunming, Yunnan, China
      920th Hospital of Joint Logistics Support Force
    2021-03-01
    Mar 1, 2021
    N
    Carfilzomib, Lenalidomide, and Dexamethasone for Smoldering Multiple Myeloma
    Active, not recruiting
    • Multiple Myeloma
    • Bethesda, Maryland
      National Institutes of Health Clinical Center, 9000 Rockville Pi
    2021-10-22
    Oct 22, 2021
    J
    Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients
    Recruiting
    • Multiple Myeloma
    • Gallium-68 labelled DOTA-conjugated SSTR targeting peptide PET/CT
    • Brussels, Belgium
      Jules Bordet Institute
    2021-10-07
    Oct 7, 2021
    M
    Immune Profiling in Multiple Myeloma
    Recruiting
    • Multiple Myeloma
      • Torino, TO, Italy
        Aou Citta' Della Salute E Della Scienza Di Torino
      2021-04-28
      Apr 28, 2021
      O
      DARA RVD For High Risk SMM
      Recruiting
      • High-risk Smoldering Multiple Myeloma
      • Multiple Myeloma
      • Boston, Massachusetts
      • +1 more
      2021-10-18
      Oct 18, 2021
      C
      Safety and Efficacy of BCMA-Targeted CAR-T Therapy for Relapsed/Refractory Multiple Myeloma
      Recruiting
      • Multiple Myeloma
      • +2 more
      • BCMA CAR-T cells
      • Chongqing, Chongqing, China
        Chongqing University Cancer Hospital
      2021-03-01
      Mar 1, 2021
      U
      Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma
      Not yet recruiting
      • Relapsed/Refractory Multiple Myeloma
      • Belantamab Mafodotin, Cyclophosphamide and Dexamethasone
      • (no location specified)
      2021-10-08
      Oct 8, 2021
      M
      LCI-HEM-MYE-CRD-002: Carfilzomib-Revlimid-Dexamethasone-Elotuzumab in Relapsed/Refractory Multiple Myeloma
      Active, not recruiting
      • Multiple Myeloma
      • Charlotte, North Carolina
        Levine Cancer Institute
      2021-10-01
      Oct 1, 2021
      U
      Virtual Exercise for Multiple Myeloma - 2021
      Completed
      • Multiple Myeloma
      • Exercise
      • Edmonton, Alberta, Canada
        University of Alberta/ Cross Cancer Institute
      2021-09-16
      Sep 16, 2021
      H
      MGUS, SMM, and MM Patient Experience With Coronavirus 19 (COVID-19) Survey
      Recruiting
      • Multiple Myeloma
      • +3 more
      • Questionnaire
      • Lehi, Utah
        HealthTree.org (Online)
      2021-08-02
      Aug 2, 2021
      D
      A Phase II Trial If Nivolumab, Lenalidomide and Dexamethasone in High Risk Smoldering Myeloma
      Suspended
      • Smoldering Multiple Myeloma
      • Boston, Massachusetts
        Dana Farber Cancer Institute
      2021-02-01
      Feb 1, 2021
      M
      Autologous Transplant for Multiple Myeloma - 2020
      Completed
      Has Results
      • Multiple Myeloma
      • Stem Cell Transplant
      • +3 more
      • Minneapolis, Minnesota
        Masonic Cancer Center, University of Minnesota
      2021-11-07
      Nov 7, 2021
      U
      The Myeloma Pack: A Multi-Modality Educational Intervention Strategy to Engage Patients With Multiple Myeloma
      Active, not recruiting
      • Multiple Myeloma
      • ARM A EARLY INTERVENTION GROUP
      • ARM B DELAYED INTERVENTION GROUP
      • Birmingham, Alabama
        University of Alabama at Birmingham
      2021-10-19
      Oct 19, 2021
      T
      Rapid-infusion Isatuximab in Relapsed/Refractory Multiple Myeloma
      Recruiting
      • Relapsed Multiple Myeloma
      • Refractory Multiple Myeloma
      • Rapid Infusion Isatuximab
      • San Francisco, California
        University of California San Francisco
      2021-05-28
      May 28, 2021